ACA
SPRO icon

Atlas Capital Advisors’s Spero Therapeutics SPRO Stock Holding History

Atlas Capital Advisors’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-727
Closed -$1.45K – 951
2022
Q3 		$1.45K Buy
+727
New +$723 ﹤0.01% 851
2022
Q2 		– Sell
-727
Closed -$6.33K – 1022
2022
Q1 		$6.33K Hold
727
– – ﹤0.01% 766
2021
Q4 		$11.6K Hold
727
– – ﹤0.01% 700
2021
Q3 		$13.4K Hold
727
– – ﹤0.01% 684
2021
Q2 		$10.1K Buy
+727
New +$10.2K ﹤0.01% 741
2021
Q1 		– Sell
-1
Closed -$19 – 828
2020
Q4 		$19 Buy
+1
New +$16 ﹤0.01% 644

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Atlas Capital Advisors's SPRO Position: Q4 2022 in Review

Atlas Capital Advisors sold out of Spero Therapeutics (SPRO) in Q4 2022, closing a stake of 727 shares — an estimated $1.45K sold.

Atlas Capital Advisors first reported a position in SPRO in Q4 2020 and held it in 6 quarters. The position peaked at $13.4K in Q3 2021. 60 funds tracked by Wall St. Rank hold SPRO as of Q4 2022.

  • Atlas Capital Advisors reported no remaining Spero Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Atlas Capital Advisors sold 727 Spero Therapeutics shares in Q4 2022, an estimated $1.45K.
  • Atlas Capital Advisors first reported a position in Spero Therapeutics in Q4 2020 and held it in 6 quarters.
  • Atlas Capital Advisors's Spero Therapeutics position peaked at $13.4K in Q3 2021.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2022.

Based on Atlas Capital Advisors's 13F filing for Q4 2022, filed 15 Feb 2023.